Targets › FE
1 program from 1 company in 2 trials: 2 Phase 3; Hematology; next expected readout Mar 2027.
Open in Phaseline: the race on FE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| George Washington University | Multiple Micronutrient Supplements with 45 mg of elemental iron Iron supplementation (45 mg elemental iron) with 14 additional micronutrients (UNIMMAP for | FE | Phase 3 | Pregnancy Related | Mar 2027 |
Pregnancy Related (2)
–
George Washington University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.